Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  17,244 results for ""Drug Substitution""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

The Science of Biosimilars-Updating Interchangeability.

  • Authors : Cavazzoni P; Center for Drug Evaluation, US Food and Drug Administration, Silver Spring, Maryland.; Yim S

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/standards ; United States Food and Drug Administration*

  • Source: JAMA [JAMA] 2024 Oct 15; Vol. 332 (15), pp. 1235-1236.Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis.

  • Authors : Song SH; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.; Woo SJ

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Adalimumab*/Adalimumab*/Adalimumab*/administration & dosage ; Visual Acuity*

  • Source: Ocular immunology and inflammation [Ocul Immunol Inflamm] 2024 Oct; Vol. 32 (8), pp. 1755-1759. Date of Electronic Publication: 2024 Jan 09.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9312169 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.

  • Authors : Errichetti E; University Hospital 'Santa Maria della Misericordia,' Udine, Italy. .; Wolf P

Subjects: Psoriasis*/Psoriasis*/Psoriasis*/drug therapy ; Ustekinumab*/Ustekinumab*/Ustekinumab*/therapeutic use ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Acta dermato-venereologica [Acta Derm Venereol] 2024 Sep 05; Vol. 104, pp. adv41053. Date of Electronic Publication: 2024 Sep 05.Publisher: Society for the Publication of Acta Dermato-Venereologica Country of Publication: Sweden NLM ID: 0370310 Publication Model: Electronic Cited

Record details

Connect Read More Add to Saved list
×
Academic Journal

Real-world utilisation and switching between Janus kinase inhibitors in Australian patients with rheumatoid arthritis in the OPAL dataset.

  • Authors : Ciciriello S; OPAL Rheumatology Ltd, Sydney, NSW; and Royal Melbourne Hospital, Melbourne, VIC, Australia.

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/Janus Kinase Inhibitors*/therapeutic use ; Drug Substitution*

  • Source: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2024 Sep; Vol. 42 (9), pp. 1763-1772. Date of Electronic Publication: 2024 May 01.Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Effectiveness and Safety of Early Versus Routine Switching from Low-Molecular-Weight Heparin to Maintenance Therapy of Rivaroxaban for Acute Iliofemoral Vein Thrombosis: A Retrospective Cohort Study.

  • Authors : Hou W; Department of Pharmacy, Tianjin Hospital, Tianjin, China.; Fang D

Subjects: Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/adverse effects ; Rivaroxaban*/Rivaroxaban*/Rivaroxaban*/administration & dosage ; Venous Thrombosis*/Venous Thrombosis*/Venous Thrombosis*/drug therapy

  • Source: Annals of vascular surgery [Ann Vasc Surg] 2024 Sep; Vol. 106, pp. 152-161. Date of Electronic Publication: 2024 May 28.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8703941 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Can we predict the risk factors for switching due to ineffectiveness in the first year of therapy with bDMARD in patients with rheumatoid arthritis?

  • Authors : Martins A; Rheumatology Department, Centro Hospitalar Universitário São João, Porto, Portugal. Electronic address: .; Pimenta S

Subjects: Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/complications ; Antirheumatic Agents*/Antirheumatic Agents*/Antirheumatic Agents*/therapeutic use

  • Source: Reumatologia clinica [Reumatol Clin (Engl Ed)] 2024 Aug-Sep; Vol. 20 (7), pp. 380-385.Publisher: Elsevier Doyma Country of Publication: Spain NLM ID: 101717526 Publication Model: Print Cited Medium: Internet ISSN: 2173-5743

Record details

Read More Add to Saved list
×
Academic Journal

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.

  • Authors : Nam H; The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.; Division of Hepatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.

Subjects: Tenofovir*/Tenofovir*/Tenofovir*/therapeutic use ; Tenofovir*/Tenofovir*/Tenofovir*/administration & dosage ; Tenofovir*/Tenofovir*/Tenofovir*/adverse effects

  • Source: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Aug; Vol. 39 (8), pp. 1673-1683. Date of Electronic Publication: 2024 May 01.Publisher: Blackwell Scientific Publications Country of Publication: Australia NLM ID: 8607909 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Risk Factors for Meeting Criteria for Switching from Bevacizumab to Aflibercept When Treating Eyes with Diabetic Macular Edema and Visual Acuity of < 20/40.

Subjects: Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/Receptors, Vascular Endothelial Growth Factor*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/therapeutic use ; Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/Recombinant Fusion Proteins*/administration & dosage

  • Source: Ophthalmology [Ophthalmology] 2024 Aug; Vol. 131 (8), pp. 967-974. Date of Electronic Publication: 2024 Feb 08.Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.

Subjects: Etanercept*/Etanercept*/Etanercept*/therapeutic use ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/economics

  • Source: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Aug 01; Vol. 63 (8), pp. 2082-2092.Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/Inflammatory Bowel Diseases*/drug therapy ; Drug Substitution*

  • Source: Arquivos de gastroenterologia [Arq Gastroenterol] 2024 Jul 19; Vol. 61, pp. e24046. Date of Electronic Publication: 2024 Jul 19 (Print Publication: 2024).Publisher: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia Country of Publication: Brazil NLM ID: 15310600R Publication Model: eCollection

Record details

Read More Add to Saved list
×
  • 1-10 of  17,244 results for ""Drug Substitution""